Trade-Ideas: Dyax (DYAX) Is Today's

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified Dyax ( DYAX) as a "dead cat bounce" (down big yesterday but up big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Dyax as such a stock due to the following factors:

  • DYAX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $37.9 million.
  • DYAX has traded 110,438 shares today.
  • DYAX is up 3.3% today.
  • DYAX was down 6.7% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in DYAX with the Ticky from Trade-Ideas. See the FREE profile for DYAX NOW at Trade-Ideas

More details on DYAX:

Dyax Corp., a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and other plasma-kallikrein-mediated (PKM) disorders. It offers KALBITOR for the treatment of acute attacks of HAE. Currently there are 7 analysts that rate Dyax a buy, no analysts rate it a sell, and 1 rates it a hold.

The average volume for Dyax has been 1.9 million shares per day over the past 30 days. Dyax has a market cap of $3.5 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.49 and a short float of 4.2% with 5.30 days to cover. Shares are up 82.2% year-to-date as of the close of trading on Thursday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Shire to Acquire Biopharma Company Baxalta in $32B Deal

The Nominees for Best Biopharma CEO of 2015 Are...

3 Drugs Stocks Moving The Industry Upward

Dyax (DYAX) Moving On Heavy Volume In The Pre-Market Hours

OPEC Begins Meeting Today, Saudis May Cut Oil Production